Imatinib Stada (Imatinib)

Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT, and PDGFR tyrosine kinases, locking them in an inactive state. This blocks downstream signaling pathways essential for cancer cell proliferation and survival, leading to apoptosis of the malignant cells while sparing most normal tissues.

The dosage of Imatinib Stada is individualized by the treating physician based on the specific indication, disease stage, patient weight, and tolerability. Only a qualified healthcare professional can determine the appropriate regimen for each patient.

Safety data for Imatinib Stada in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should discuss contraception and risk with their physician.

To request Imatinib Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor approved and remains a standard of care for several cancers. Compared with newer agents, it has a well‑characterised safety profile and extensive clinical experience, though some newer inhibitors may offer activity against resistant mutations or different dosing schedules.

Imatinib Stada should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight to maintain its stability throughout its shelf life.

Imatinib Stada is taken orally, usually with a glass of water. It can be swallowed with or without food, but patients should follow the prescribing physician’s instructions regarding timing and any dietary considerations.

Serious risks include severe neutropenia, hepatotoxicity, cardiac failure, pulmonary hypertension, and rare cases of severe bleeding. Patients should be monitored regularly for blood counts, liver function, and cardiac health, and any concerning symptoms should be reported promptly.

Imatinib Stada is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for patients with pre‑existing severe liver disease, uncontrolled heart failure, or those taking medications that may cause dangerous interactions.